

Avantium nominates Rob van Leen for appointment to the Supervisory Board

AMSTERDAM, 3 April 2019, 17:45 CET – Avantium announces the nomination of Rob van Leen for appointment to its Supervisory Board. The nomination will be submitted to the Avantium Annual General Meeting of Shareholders on 15 May 2019.

Rob van Leen is currently Chief Innovation Officer at Royal DSM N.V. and member of the Executive Committee. Prior to this role, from 1987 until 2006, he held several senior business roles at DSM. Rob van Leen has a PhD in Molecular Biology from the University of Nijmegen and an MSc in Biologics from University of Utrecht. He also holds an MBA degree from Nyenrode University.

Chairman of the Supervisory Board Kees Verhaar commented: "We are very pleased to nominate Rob van Leen for appointment to the Supervisory Board. His extensive experience in our industry as well as his experience with accelerating and supporting innovation will be of indispensable value to our board."

About Avantium

Avantium is a leading technology development company and a forerunner in renewable chemistry. We develop technologies that enable production of sustainable products from plant-based raw materials. We work in partnership with like-minded companies around the globe to create revolutionary renewable chemistry solutions from invention to commercial scale. We also help clients in catalytic research by providing proprietary systems and services to improve their products and processes.

Avantium's shares are listed on Euronext Amsterdam and Euronext Brussels (symbol: AVTX). Its offices and headquarters are in Amsterdam, the Netherlands.

For more information:

Caroline van Reedt Dortland, Director Communications, Avantium +31-20-5860110 / +31-613400179, caroline.vanreedt-dortland@avantium.com